NUEVA ESPERANZA PARA DIABETES TIPO 1

June 22nd, 2026

Dear Friend,

We are very excited to provide a major update on the BCG clinical trials program at MGH. On June 7th at the Scientific Session of the American Diabetes Association (ADA) we presented the results of the BCG Phase II clinical trial. There were two presentations: eight-year follow up of adults with juvenile-onset type 1 diabetes (T1D), and eight year follow up on an exploratory group of adults with latent autoimmune diabetes in adults (LADA). All subjects were given a total of six BCG shots over five years. Both studies confirmed the results of earlier trials and demonstrated that BCG can create durable and significant improvements in the primary diabetes biomarkers: c-peptide, HbA1c, insulin use and time in range. This is the first time any immunotherapy has reversed the progression of autoimmune diabetes in adults with long-standing diabetes. There are copies of the two presentations and a selection of news coverage on the lab’s web site. This is an accomplishment that we owe to all of the friends and families who have supported us over the years. We are not finished. There are currently 250 children enrolled in our pediatric trials, and the goal of getting BCG approved as an affordable therapy for everyone with type 1 is closer than ever before. We hope you will continue with us on this journey. These trials are funded entirely by "little philanthropy" -- the generosity of people impacted by type 1 diabetes, NOT corporations and "large pharma." Please follow us on social media (@faustmanlab) for more updates. We also have a new podcast series "Faustman Lab Notes" on Spotify. Thank you again and have a great summer.

Sincerely,